Gå direkt till innehåll

Kategorier: equity report

  • Read Redeye's new equity report on Alzinova AB

    Read Redeye's new equity report on Alzinova AB

    Redeye AB has revisited the Alzinova equity story with the initiation of clinical trials with ALZ-101, our vaccine candidate in Alzheimer’s, an indication with a vast unmet medical need. "Now is the time when the case could start to heat up."